Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy.

Pharmaceutics · 2022 · PMC9502377 · PMID 36145656

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a definite trendno p-value reported

This status displayed a definite trend over time ( Figure 3 B), implying that Ce6-CAT/PEGDA alleviates tumor hypoxia and simultaneously disrupts the ITM.

also in 427 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.